Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 206, Issue 4, 2012, Pages 512-522

  Abzug, Mark J ^a   Qin, Min ^b   Levin, Myron J ^a   Fenton, Terence ^b   Beeler, Judy A ^c   Bellini, William J ^d   Audet, Susette ^c   Sowers, Sun Bae ^d   Borkowsky, William ^e   Nachman, Sharon A ^f   Pelton, Stephen I ^g   Rosenblatt, Howard M ^h,i  

^a UNIVERSITY OF COLORADO   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g BOSTON MEDICAL CENTER   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ DELL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONCENTRATION (PARAMETERS); DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MUMPS; PRESCHOOL CHILD; PRIORITY JOURNAL; RUBELLA; SCHOOL CHILD; SEROLOGY; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; METHODOLOGY; MULTICENTER STUDY; SERODIAGNOSIS; VIRUS CULTURE;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; MALE; MEASLES VACCINE; NEUTRALIZATION TESTS; VIRAL LOAD; VIRAL PLAQUE ASSAY;

EID: 84867021951     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis386     Document Type: Article

References (41)

1. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267:1237-41.
2. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989; 261:2512-6.
3. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Populationbased study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11:1008-14.
4. Al-Attar I, Reisman J, Muehlmann M, McIntosh K. Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995; 14:149-51.
5. Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996; 97:653-7.
6. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637-42.
7. Brena AE, Cooper ER, Cabral HJ, Pelton SI. Antibody response to measles and rubella vaccine by children with HIV infection. J Acquir Immune Defic Syndr 1993; 6:1125-9.
8. Brunell PA, Vimal V, Sandu M, Courville TM, Daar E, Israele V. Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:540-8.
9. Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009; 28:295-9.
10. Fowlkes A, Witte D, Beeler J, et al. Persistence of vaccine-induced measles antibody beyond 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J Infect Dis 2011; 204:S149-57.
11. Helfand RF, Witte D, Fowlkes A, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008; 198:1457-65.
12. Hilgartner MW, Maeder MA, Mahoney EM, et al. Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia growth and development study. Am J Hematol 2001; 66:92-8.
13. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347-55.
14. Nair N, Moss WJ, Scott S, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virusspecific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031-8.
15. Rudy BJ, Rutstein RM, Pinto-Martin J. Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr 1994; 125:72-4.
16. Thaithumyanon P, Punnahitananda S, Thisyakorn U, Praisuwanna P, Ruxrungtham K. Immune responses to measles immunization and the impacts on HIV-infected children. Southeast Asian J Trop Med Public Health 2000; 31:658-62.
17. Walter EB, Katz SL, Bellini WJ. Measles immunity in HIV-infected children. Pediatr AIDS HIV Infect 1994; 5:300-4.
18. Aurpibul L, Puthanakit T, Kanjanavanit S, Sirisanthana T, Sirisanthana V. Measles outbreak in an orphanage: HIV-infected children on antiretroviral therapy are still at risk. Pediatr Infect Dis J 2010; 29:167-9.
19. Moss WJ, Fisher C, Scott S, et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 2008; 46:523-7.
20. Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008; 37:356-67.
21. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virusinfected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-9.
22. Abzug MJ, Song LY, Fenton T, et al. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 2007; 120:e1190-202.
23. Abzug MJ, Warshaw M, Rosenblatt HM, et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009; 200:935-46.
24. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-60.
25. Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66.
26. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
27. Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J Infect Dis 2004; 189:S123-30.
28. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-22.
29. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virusinfected children. Clin Infect Dis 2001; 32:1090-4.
30. Tejiokem MC, Gouandjika I, Beneiguel L, et al. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS One 2007; 2: e1260.
31. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenza type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:e641-4.
32. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10:630-42.
33. American Academy of Pediatrics. Measles. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2009 report of the committee of infectious diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009:448-9.
34. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1415-8.
35. Belaunzaran-Zamudio PF, Garcia-Leon ML, Wong-Chew RM, et al. Early loss of measles antibodies after MMR vaccine among HIVinfected adults receiving HAART. Vaccine 2009; 27:7059-64.
36. Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009; 106:7939-44.
37. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIVinfected children with varicella vaccine. J Pediatr 2001; 139:305-10.
38. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis 2006; 194:247-55.
39. Nilsson A, Chiodi F. Measles outbreak in Africa - is there a link to the HIV epidemic? PLoS Pathog 2011; 7:1-3.
40. Abzug MJ, Pelton SI. Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox. J Infect Dis 2009; 199:1109-11.
41. Rainwater-Lovett K, Moss WJ. The urgent need for recommendations on revaccination of HIV-infected children after successful antiretroviral therapy. Clin Infect Dis 2010; 51:634-5.